 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Verastem
VSTM
conference date: May 9, 2023 press release only
Verastem Cancer Therapy Should Get Traction, Raise Stock Price March 23, 2019 at Seeking Alpha
| 2023 | |||
| Verastem Q4 2022 press release |
Verastem Q1 2023 press release |
||
| March 14, 2023 | May 9, 2023 | ||
| 2022 | |||
| Verastem Q4 2021 press release |
Verastem Q1 2022 press release |
Verastem Q2 2022 press release |
Verastem Q3 2022 press release |
| March 28, 2022 | May 9, 2022 | August 8, 2022 | Nov. 3, 2022 |
| 2021 | |||
| Verastem Q4 2020 press release |
Verastem Q1 2021 press release |
Verastem Q2 2021 press release |
Verastem Q3 2021 press release |
| March 18, 2021 | May 11, 2021 | Aug. 2, 2021 | Nov. 4, 2021 |
| 2020 | |||
| Verastem Q4 2019 |
Verastem Q1 2020 |
Verastem Q2 2020 |
Verastem Q3 2020 press release |
| Feb. 28, 2020 | May 7, 2020 | Aug. 10, 2020 | Nov. 9, 2020 |
| 2019 | |||
| Verastem Q4 2018 |
Verastem Q1 2019 |
Verastem Q2 2019 |
Verastem Q3 2019 |
| March 12, 2019 | May 9, 2019 | August 1, 2019 | Oct. 29, 2019 |
2018 |
|||
March 13, 2018 |
May 3, 2018 |
August 8, 2018 |
Nov. 7, 2018 |
Verastem (VSTM) is a commercial-stage biotechnology company specializing in cancer therapies.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| CLDX |
| CLSN |
| CELG |
| EPZM |
| GILD |
| GLYC |
| ILMN |
| INCY |
| INO |
| ISRG |
| MCHP |
| PLX |
| REGN |
| RNA |
| SAGE |
| SGEN |
| TTPH |
| VBLT |
| VRTX |
| XLRN |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2022 William P. Meyers